Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case–control study

Cancer Causes and Control

Volumn 27, Issue 1, 2016, Pages 69-80

  Brändstedt, Johan ^a   Almquist, Martin ^a   Ulmert, David ^a   Manjer, Jonas ^a   Malm, Johan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calcium; Prostate cancer; PTH; Tumor aggressiveness; Vitamin D

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPATHOLOGY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN FUNCTION; SWEDEN; TUMOR INVASION; VITAMIN BLOOD LEVEL; AGED; BLOOD; DIET; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

AGED; CALCIUM; CASE-CONTROL STUDIES; DIET; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PARATHYROID HORMONE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 84953366066     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0684-3     Document Type: Article

References (62)

1. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859–864
2. Schwartz GG, Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10(5A):1307–1311
3. Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control CCC 16(2):83–95. doi:10.1007/s10552-004-1661-4
4. Willis MS, Wians FH (2003) The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clin Chim Acta 330(1–2):57–83
5. Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp Biol Med (Maywood) 229(4):277–284
6. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2(5):467–472
7. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control CCC 6(3):235–239
8. Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR (2004) Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89–90(1–5):533–537
9. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A, Holick MF (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control CCC 9(4):425–432
10. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case–control study in the Nordic countries. Int J Cancer J Int Cancer 108(1):104–108
11. Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER (2005) Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 14(3):586–589. doi:10.1158/1055-9965.EPI-04-0319
12. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4(3):e103
13. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB (2008) Serum vitamin D concentration and prostate cancer risk: a nested case–control study. J Natl Cancer Inst 100(11):796–804
14. Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA (2007) Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 16(12):2784–2786. doi:10.1158/1055-9965.EPI-07-0672
15. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Athene Lane J, Martin RM (2011) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer J Int Cancer. doi:10.1002/ijc.27327
16. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E (2007) Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67(9):911–923. doi:10.1002/pros.20570
17. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, Hoffman AR, Barrett-Connor E, Orwoll E, Beer TM (2010) Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control CCC 21(8):1297–1303. doi:10.1007/s10552-010-9557-y
18. Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN (2010) Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer 46(5):932–936. doi:10.1016/j.ejca.2009.12.030
19. Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjonneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kroger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, Palli D, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larranaga N, Gonzalez CA, Arguelles MV, Sanchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ (2009) Serum vitamin D and risk of prostate cancer in a case–control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol 169(10):1223–1232. doi:10.1093/aje/kwp022
20. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, Mucci LA, Giovannucci E (2011) Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS ONE 6(4):e18625. doi:10.1371/journal.pone.0018625
21. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI (2010) Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988–2006). Cancer Res 70(21):8587–8597. doi:10.1158/0008-5472.CAN-10-1420
22. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Sykes J, Lockwood G, van der Kwast TH (2013) Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 105(14):1050–1058. doi:10.1093/jnci/djt151
23. samverkan Rci (2012) Nationell kvalitetsrapport för diagnosår 2012 från Nationella prostatacancerregistret (NPCR)
24. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA (1997) Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30(3):183–187
25. Murray RM, Grill V, Crinis N, Ho PW, Davison J, Pitt P (2001) Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 86(9):4133–4138
26. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM (2005) Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res 11(24 Pt 1):8680–8685. doi:10.1158/1078-0432.CCR-05-1237
27. Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, Torta M, Reimondo G, Poggio M, Scarpa RM, Angeli A, Dogliotti L, Berruti A (2009) Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 12(1):94–99. doi:10.1038/pcan.2008.10
28. Silverberg SJ (2000) Natural history of primary hyperparathyroidism. Endocrinol Metab Clin N Am 29(3):451–464
29. Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58(3):442–447
30. Skinner HG, Schwartz GG (2009) A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomark Prev 18(2):575–578
31. Skinner HG, Schwartz GG (2008) Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 17(9):2302–2305. doi:10.1158/1055-9965.EPI-08-0365
32. Schwartz GG, Skinner HG (2012) A prospective study of total and ionized serum calcium and time to fatal prostate cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 21(10):1768–1773. doi:10.1158/1055-9965.EPI-12-0585
33. Brandstedt J, Almquist M, Manjer J, Malm J (2012) Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case–control study. Cancer Causes Control CCC 23(8):1377–1385. doi:10.1007/s10552-012-9948-3
34. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G (2001) The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 10(6):489–499
35. Wallstrom (2002) Diet, lifestyle, antioxidants and biomarkers of cancer risk. An epidemiological report from the Malmö Diet and cancer cohort. Thesis, Lund University, Malmö
36. Anker P, Wieland E, Ammann D, Dohner RE, Asper R, Simon W (1981) Neutral carrier based ion-selective electrode for the determination of total calcium in blood serum. Anal Chem 53(13):1970–1974
37. Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94(9):2511–2516. doi:10.1002/cncr.10492
38. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A (2007) The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 85(3):649–650
39. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, Weinstein SJ (2011) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case–control study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 20(9):1850–1860. doi:10.1158/1055-9965.EPI-11-0403
40. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D (2004) Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 38(6):732–744. doi:10.1016/j.ypmed.2004.01.005
41. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA (2014) Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 23(8):1494–1504. doi:10.1158/1055-9965.EPI-14-0115
42. Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML (2014) Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 23(8):1484–1493. doi:10.1158/1055-9965.EPI-13-1340
43. Schwartz GG (2014) Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 23(8):1447–1449. doi:10.1158/1055-9965.EPI-14-0520
44. Schwartz GG (2008) Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 17(3):478–483. doi:10.1158/1055-9965.EPI-07-2747
45. Gd L (1962) Hypocalcemia and hypophosphatemia accompanying osteoblastic osseous metastases: studies of calcium and phosphate metabolism and parathyroid function. Ann Intern Med 1962(56):676–677
46. Liao J, Schneider A, Datta NS, McCauley LK (2006) Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 66(18):9065–9073
47. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ (1994) Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 43(5):675–679
48. Gensure RC, Gardella TJ, Juppner H (2005) Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 328(3):666–678. doi:10.1016/j.bbrc.2004.11.069
49. Skinner HG, Schwartz GG (2009) The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 18(11):2869–2873. doi:10.1158/1055-9965.EPI-09-0730
50. Aydin O, Eren E, Yalcinkaya S, Yilmaz N, Eroglu M, Ellidag HY (2014) Positive correlation of serum parathormone and prostate specific antigen levels in prostate cancer. Bratisl Lek Listy 115(3):171–174
51. Kim WT, Choi YD, Park C, Kim YW, Yun SJ, Kim IY, Kim WJ (2011) Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia. Prostate 71(11):1210–1215. doi:10.1002/pros.21336
52. Pero RW, Olsson A, Bryngelsson C, Carlsson S, Janzon L, Berglund G, Elmstahl S (1998) Quality control program for storage of biologically banked blood specimens in the Malmo Diet and Cancer Study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 7(9):803–808
53. Hollis BW (2008) Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 88(2):507S–510S
54. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control CCC 15(3):255–265
55. Meng JE, Hovey KM, Wactawski-Wende J, Andrews CA, Lamonte MJ, Horst RL, Genco RJ, Millen AE (2012) Intraindividual variation in plasma 25-hydroxyvitamin D measures 5 years apart among postmenopausal women. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 21(6):916–924. doi:10.1158/1055-9965.EPI-12-0026
56. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, Minchinela J, Perich C, Simon M (1999) Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 59(7):491–500
57. Gallagher SK, Johnson LK, Milne DB (1989) Short-term and long-term variability of indices related to nutritional status. I: Ca, Cu, Fe, Mg, and Zn. Clin Chem 35(3):369–373
58. Ankrah-Tetteh T, Wijeratne S, Swaminathan R (2008) Intraindividual variation in serum thyroid hormones, parathyroid hormone and insulin-like growth factor-1. Ann Clin Biochem 45(Pt 2):167–169
59. Viljoen A, Singh DK, Twomey PJ, Farrington K (2008) Analytical quality goals for parathyroid hormone based on biological variation. Clin Chem Lab Med 46(10):1438–1442
60. Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27–33
61. Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C (2009) Vitamin D and calcium insufficiency-related chronic diseases: an emerging world-wide public health problem. Int J Environ Res Public Health 6(10):2585–2607
62. Hoffman RM, Stone SN, Espey D, Potosky AL (2005) Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer 5:27